Povorcitinib

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from povorcitinib treatment, Incyte announced in a press release.

Incyte has entered into a collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib, the companies announced in a press release.

SAN DIEGO — In this Healio video perspective, Martin Metz, MD, discusses the results from a randomized, double-blind, placebo-controlled study of the Janus kinase inhibitor povorcitinib for the treatment of prurigo nodularis.